ResMed (RMD) has continually demonstrated
strength as a growth stock, repeatedly surpassing earnings and revenue estimates. Despite stock-price volatility, the fundamentals of the company remain solid. They have reported strong Q1, Q2, Q3 results with increasing revenues and strong margin expansion. Notably, ResMed made significant strides in
investor relations by appointing a 20-year finance expert from Illumina. They have also been innovating, launching the
NightOwl device to simplify home sleep apnea testing across the US, and acquiring
VirtuOx to expand their reach. Citi upgrades and
analyst price target adjustments from KeyBanc and RBC Capital reflect positive expectations. However, despite stronger-than-expected Q4 sales, the stock stumbled, leading to questions about its financial health. The company's association with the rugby tour to promote sleep health led to its identification as an 'Official Sleep Partner'. An investigation into potential violations of securities laws remains ongoing. Multiple analysts laud ResMed's consistent growth, while its price target was reduced by Mizuho. ResMed announced a
consistent quarterly dividend but faced insider selling from CEO Michael Farrell, seemingly sparking hesitancy.
Resmed RMD News Analytics from Tue, 27 Aug 2024 07:00:00 GMT to Thu, 15 May 2025 13:53:10 GMT -
Rating 8
- Innovation 8
- Information 9
- Rumor -5
